natgillin/translations-raw huggingface dataset:
Local reactions may very commonly appear in the vaccinated animals in the form of small intramuscular granulomas up to 0.7 cm of diameter, which resolve in a maximum of 10 days. 
Pri brejih ovcah se v prvih 4 urah po cepljenju zelo pogosto pojavi prehodno povišanje rektalne temperature, ne več kot za 0,8° C. Zelo pogoste so pri cepljenih živalih lokalne reakcije v obliki difuznih oteklin ali subkutanih granulomov, premera do največ 8 cm. Reakcija v obliki manjšega granuloma, premera manj kot 0,5 cm lahko traja najmanj 97 dni.
Cattle: The safety and efficacy of the vaccine has not been established in pregnant cattle. 
Varnosti in učinkovitosti cepiva pri plemenskih samcih niso ugotavljali.
Further information on Ambrisentan Mylan can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/ambrisentan-mylan. 
Nadaljnje informacije za zdravilo Ambrisentan Mylan so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/ambrisentan-mylan.
The ‘class' reflects the severity of the disease: ‘class II' involves slight limitation of physical activity and ‘class III' involves marked limitation of physical activity. 
Razred odraža resnost bolezni: razred II pomeni rahlo omejitev telesne zmogljivosti, razred III pa znatno omejitev telesne zmogljivosti.
As a result, the amount of oxygen that can get into the blood in the lungs is reduced, making physical activity more difficult. 
Posledično se zmanjša količina kisika, ki lahko pride v kri v pljučih, zaradi česar je telesna dejavnost otežena.
What measures are being taken to ensure the safe and effective use of Ambrisentan Mylan? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ambrisentan Mylan?
Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Volibris, and do not need to be repeated for Ambrisentan Mylan. 
Študije o koristih in tveganjih učinkovine pri odobrenem načinu uporabe so že bile izvedene z referenčnim zdravilom Volibris, zato jih ni treba ponoviti za zdravilo Ambrisentan Mylan.
Ambrisentan Mylan is available as tablets (5 and 10 mg). 
Zdravilo Ambrisentan Mylan je na voljo v obliki tablet (5 in 10 mg).
Ambrisentan Mylan is used in patients with class II or III disease. 
Zdravilo Ambrisentan Mylan se uporablja pri bolnikih z boleznijo razreda II ali III.
Because Ambrisentan Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Ambrisentan Mylan generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
As for every medicine, the company provided studies on the quality of Ambrisentan Mylan. 
Tako kot za vsako zdravilo je podjetje predložilo študije o kakovosti zdravila Ambrisentan Mylan.
The European Medicines Agency concluded that, in accordance with EU requirements, Ambrisentan Mylan has been shown to have comparable quality and to be bioequivalent to Volibris. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Ambrisentan Mylan primerljivo raven kakovosti in je bioekvivalentno referenčnemu zdravilu Volibris.
When taken with ciclosporin (a medicine that reduces the activity of the immune system) the dose of Ambrisentan Mylan should be 5 mg daily and the patient should be closely monitored by their doctor. 
Kadar se zdravilo Ambrisentan Mylan jemlje sočasno s ciklosporinom (zdravilom, ki zmanjšuje aktivnost imunskega sistema), mora biti odmerek zdravila 5 mg na dan, bolniki pa morajo biti pod skrbnim nadzorom svojega zdravnika.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ambrisentan Mylan have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ambrisentan Mylan upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
This means that Ambrisentan Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Volibris. 
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Volibris.
The company that markets Ambrisentan Mylan will provide a patient card containing important information on the medicine's side effects and the need to avoid pregnancy during treatment. 
Podjetje, ki trži zdravilo Ambrisentan Mylan, bo bolnikom priskrbelo kartico, ki bo vključevala pomembne informacije o neželenih učinkih zdravila in o potrebi po preprečevanju zanositve med zdravljenjem.
For more information about using Ambrisentan Mylan, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Ambrisentan Mylan glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
As for all medicines, data on the use of Ambrisentan Mylan are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Ambrisentan Mylan stalno spremljajo.
Side effects reported with Ambrisentan Mylan are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Ambrisentan Mylan, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
An overview of Ambrisentan Mylan and why it is authorised in the EU 
Pregled zdravila Ambrisentan Mylan in zakaj je odobreno v EU
What are the benefits and risks of Ambrisentan Mylan? 
Kakšne so koristi in tveganja zdravila Ambrisentan Mylan?
Other information about Ambrisentan Mylan 
Druge informacije o zdravilu Ambrisentan Mylan
Why is Ambrisentan Mylan authorised in the EU? 
Zakaj je bilo zdravilo Ambrisentan Mylan odobreno v EU?
Ambrisentan Mylan is a medicine that is used alone or combined with other medicines to treat adults with pulmonary arterial hypertension (PAH). 
Ambrisentan Mylan je zdravilo, ki se uporablja kot samostojno zdravilo ali v kombinaciji z drugimi zdravili za zdravljenje odraslih s pljučno arterijsko hipertenzijo (PAH).
Ambrisentan Mylan contains the active substance ambrisentan and is a ‘generic medicine'. 
Zdravilo Ambrisentan Mylan vsebuje učinkovino ambrisentan in je „generično zdravilo“.
It causes high blood pressure in the vessels taking blood from the heart to the lungs and reduces the 
To povzroči zelo visok krvni tlak v žilah, po katerih se kri pretaka iz srca v pljuča, in zmanjšuje pretok krvi v pljuča.
What is Ambrisentan Mylan and what is it used for? 
Kaj je zdravilo Ambrisentan Mylan in za kaj se uporablja?
PAH is abnormally high blood pressure in the arteries of the lungs. 
Pljučna arterijska hipertenzija se kaže v neobičajno visokem krvnem tlaku v pljučnih arterijah.
By blocking the effect of endothelin, Ambrisentan Mylan prevents the vessels becoming too narrow helping to lower the blood pressure and improving symptoms. 
Zdravilo Ambrisentan Mylan z zaviranjem učinka endotelina omogoči širjenje žil, kar prispeva k znižanju krvnega tlaka in olajšanju simptomov.
Ambrisentan Mylan can only be obtained with a prescription and treatment must be started by a doctor who has experience in the treatment of PAH. 
Predpisovanje in izdaja zdravila Ambrisentan Mylan je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem pljučne arterijske hipertenzije.
PAH is a debilitating disease where there is severe narrowing of the blood vessels of the lungs. 
Pljučna arterijska hipertenzija je izčrpavajoča bolezen, pri kateri pride do hude zožitve krvnih žil v pljučih.
Ambrisentan Mylan is effective in PAH with no identified cause and in PAH caused by connective tissue disease. 
Učinkovitost zdravila Ambrisentan Mylan je bila dokazana pri pljučni arterijski hipertenziji brez znanega vzroka in pljučni arterijski hipertenziji, povezani z boleznijo vezivnega tkiva.
The active substance in Ambrisentan Mylan, ambrisentan, blocks the receptors (targets) for a hormone called endothelin, which causes blood vessels to become narrow. 
Učinkovina v zdravilu Ambrisentan Mylan, ambrisentan, zavira receptorje za hormon, imenovan endotelin, ki povzroča zožitev žil.
How has Ambrisentan Mylan been studied? 
Kako je bilo zdravilo Ambrisentan Mylan raziskano?
Therefore, the Agency's view was that, as for Volibris, the benefit of Ambrisentan Mylan outweighs the identified risk and it can be authorised for use in the EU. 
Zato je menila, da koristi zdravila Ambrisentan Mylan enako kot pri zdravilu Volibris odtehtajo znana tveganja in da se zdravilo lahko odobri v EU.
Treatment is started at a dose of 5 mg daily and the doctor may increase it to 10 mg daily depending on response and any side effects experienced by the patient. 
Zdravljenje se uvede v odmerku 5 mg enkrat na dan, zdravnik pa lahko glede na odziv in neželene učinke, ki jih občuti bolnik, odmerek poveča na največ 10 mg na dan. Na 10 miligramov povečani odmerek se priporoča, kadar se zdravilo uporablja v kombinaciji s tadalafilom (drugim zdravilom za zdravljenje pljučne arterijske hipertenzije).
How is Ambrisentan Mylan used? 
Kako se zdravilo Ambrisentan Mylan uporablja?
How does Ambrisentan Mylan work? 
Kako zdravilo Ambrisentan Mylan deluje?
11 October 2019 
11. oktober 2019
What is paromomycin? 
Kaj je paromomicin?
Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/129) 
Izid napotitvenega postopka v skladu s členom 35 Direktive 2001/82/ES (EMEA/V/A/129)
The European Commission issued a decision on 11 October 2019. 
Evropska komisija je sklep izdala 11. oktobra 2019.
These included data from companies and published literature. 
Vključeni so bili podatki, ki so jih priskrbela podjetja, in podatki iz objavljene literature.
Why were veterinary medicines containing paromomycin reviewed? 
Zakaj so bila zdravila za uporabo v veterinarski medicini, ki vsebujejo paromomicin, pregledana?
The Committee also noted the possibility that inappropriate doses could lead to bacterial resistance. 
Odbor je opozoril tudi na možnost, da bi lahko neustrezni odmerki povzročili razvoj bakterijske odpornosti.
Therefore, the CVMP recommended suspending the marketing authorisations for these veterinary medicines until adequate data are available. 
Odbor CVMP je zato priporočil, da se dovoljenja za promet s temi zdravili za uporabo v veterinarski medicini začasno umaknejo, dokler ne bodo na voljo ustrezni podatki.
On 25 September 2018, the Belgian medicines authority requested that the CVMP review all available data on paromomycin's effectiveness and residue depletion (how long a medicine takes to fall below maximum residue limits (MRLs) in the animal's body). 
Belgijski organ za zdravila je 25. septembra 2018 zahteval, da odbor CVMP ponovno pregleda vse razpoložljive podatke o učinkovitosti paromomicina in izločanju ostankov (kako dolgo traja, da ostanki zdravila v telesu živali padejo pod mejno vrednost najvišjih dovoljenih količin ostankov (MRL)).
Paromomycin is an aminoglycoside antibiotic used to treat a wide range of bacterial infections and is given to pigs by injection into a muscle. 
Paromomicin je aminoglikozidni antibiotik, ki se uporablja za zdravljenje številnih bakterijskih okužb in se daje prašičem z injiciranjem v mišico.
The CVMP reviewed available data on effectiveness and residue depletion. 
Odbor CVMP je pregledal razpoložljive podatke o učinkovitosti in izločanju ostankov.
The withdrawal period is the minimum time that has to elapse before an animal treated with a medicine can be slaughtered and its meat or other animal derived products may be used for human consumption. 
Karenca je najkrajši čas, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje ter se lahko meso in drugi živalski proizvodi uporabijo za prehrano ljudi.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of these medicines do not outweigh their risks because of inadequate data supporting their use in pigs and the possibility of bacterial resistance. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da koristi teh zdravil ne odtehtajo z njimi povezanih tveganj zaradi nezadostnih podatkov o njihovi uporabi pri prašičih in možnosti razvoja bakterijske odpornosti.
The Belgian authority noted that there were different approved uses, dose schedules and withdrawal periods across the EU. 
Opozoril je, da so po EU odobrene različne uporabe, časovni razporedi odmerjanja in obdobja karence.
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that the benefits of veterinary medicines containing paromomycin given to pigs by injection into the muscle do not outweigh their risks. 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave v Odboru je odbor CVMP zaključil, da koristi zdravil za uporabo v veterinarski medicini, ki vsebujejo paromomicin in se dajejo prašičem z injiciranjem v mišico, ne odtehtajo z njimi povezanih tveganj.
Questions and answers on suspension of marketing authorisations for injectable veterinary medicines containing paromomycin given to pigs 
Vprašanja in odgovori o začasnem umiku dovoljenj za promet z zdravili za uporabo v veterinarski medicini, ki vsebujejo paromomicin za injiciranje in se uporabljajo za prašiče
On 18 July 2019, the European Medicines Agency recommended suspending the marketing authorisations for paromomycin antibiotics given to pigs by injection into a muscle. 
Evropska agencija za zdravila je 18. julija 2019 priporočila, da se dovoljenja za promet z antibiotiki, ki se dajejo prašičem z injiciranjem v mišico, začasno umaknejo.
The Committee based its opinion on the lack of adequate data on how effective these medicines are and residue depletion data. 
Svoje mnenje je utemeljil na pomanjkanju ustreznih podatkov o njihovi učinkovitosti in izločanju njihovih ostankov.
08019 - Barcelona Spain 
08019 - Barcelona Španija
Evropská 846/176a 160 00 Praha 6 
Evropská 846/176a 160 00 Praha 6 Češka
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States 
Seznam imen, farmacevtskih oblik, jakosti zdravil, poti uporabe zdravila, imetnikov dovoljenja za promet z zdravilom v državah članicah
GR-Greece 
GR-Grčija
65926 Frankfurt am Main, Deutschland 
65926 Frankfurt am Main, Nemčija
Sweden sanofi-aventis AB Box 141 42 
Švedska sanofi-aventis AB Box 141 42
Greece sanofi-aventis AEBE 348 Syngrou avenueBuilding A 
Grčija sanofi-aventis AEBE 348 Syngrou avenueBuilding A
Estonia sanofi-aventis Estonia OÜ, Pärnu mnt 139 E/2, 11317 Tallinn, Estonia 
Estonija sanofi-aventis Estonia OÜ, Pärnu mnt 139 E/2, 11317 Tallinn, Estonija
Sanofi-aventis One Onslow Street, Guildford, Surrey, GU1 4YS, United Kingdom) 
Sanofi-aventis One Onslow Street, Guildford, Surrey, GU1 4YS, Velika Britanija)
Sanofi-aventis Cyprus Ltd, 14 Charalambou Mouskou street, 2015 - Nicosia, Cyprus 
Sanofi-aventis Cyprus Ltd, 14 Charalambou Mouskou street, 2015 - Nicosia, Ciper
Ireland sanofi-aventis Ireland Ltd., Citywest Business Campus, Dublin 24, Ireland 
Irska sanofi-aventis Ireland Ltd., Citywest Business Campus, Dublin 24, Irska
Sanofi-aventis France 1-13 Boulevard Romain Rolland 75014 Paris FRANCE 
Sanofi-aventis France 1-13 Boulevard Romain Rolland 75014 Paris Francija
Slovenia sanofi-aventis d.o.o, Dunajska 151, 1000 Ljubljana, Slovenia 
Slovenija sanofi-aventis d.o.o, Dunajska 151, 1000 Ljubljana, Slovenija
Sanofi-Avenstis Bulgaria EOOD, Bulgaria, 1303 Sofia, 103 Alexander Stamboliiski Blvd, fl.8 
Sanofi-Avenstis Bulgaria EOOD, Bulgarija, 1303 Sofia, 103 Alexander Stamboliiski Blvd, fl.8
Netherlands sanofi-aventis Netherlands B.V., Kampenringweg 45 DE, 2803 PE Gouda, The Netherlands 
Nizozemska sanofi-aventis Netherlands B.V., Kampenringweg 45 DE, 2803 PE Gouda, Nizozemska
Hungary sanofi-aventis Zrt. 
Madžarska sanofi-aventis Zrt.
Finland sanofi-aventis Oy Huopalahdentie 24 00350 Helsinki, Finland 
Finska sanofi-aventis Oy Huopalahdentie 24 00350 Helsinki, Finska
Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 D-65 926 Frankfurt am Main, Germany 
Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 D-65 926 Frankfurt am Main, Nemčija
SANOFI-AVENTISProdutos 
Portugalska SANOFI-AVENTISProdutos
Italy sanofi-aventis S.p.A. Viale Luigi Bodio 37/B 20158 Milan Italy 
Viale Luigi Bodio 37/B 20158 Milan Italija
Tavanic 250 250 mg Film-coated tablets 
Tavanic 250 250 mg Filmsko obložene tablete
Tavanic 500 500 mg Film-coated tablets 
Tavanic 500 500 mg Filmsko obložene tablete
Tavanic 500mg 500 mg Film-coated tablets 
Tavanic 500mg 500 mg Filmsko obložene tablete
This summary was last updated in 02-2016. 
Povzetek je bil nazadnje posodobljen MM-2016.
What measures are being taken to ensure the safe and effective use of Zurampic? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zurampic?
Patients should drink plenty of fluids throughout the day. 
Bolniki morajo čez dan popiti dovolj tekočine.
What is Zurampic and what is it used for? 
Kaj je zdravilo Zurampic in za kaj se uporablja?
The full EPAR and risk management plan summary for Zurampic can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Zurampic sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Risks such as kidney damage or heart problems are addressed in the product information. 
Tveganja, kot so poškodbe ledvic in težave s srcem, se obravnavajo v informacijah o zdravilu.
It is not intended to provide practical advice on how to use Zurampic. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Zurampic is available as 200-mg tablets. 
Zdravilo Zurampic je na voljo v obliki 200-miligramskih tablet.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Zurampic's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Zurampic večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
What benefits of Zurampic have been shown in studies? 
Kakšne koristi je zdravilo Zurampic izkazalo v študijah?
This is a summary of the European public assessment report (EPAR) for Zurampic. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zurampic.
A risk management plan has been developed to ensure that Zurampic is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Zurampic je bil pripravljen načrt obvladovanja tveganj.
Other information about Zurampic 
Druge informacije o zdravilu Zurampic
What are the risks associated with Zurampic? 
Kakšna tveganja so povezana z zdravilom Zurampic?
Zurampic was studied in two main studies involving over 1,200 adults with gout who were previously treated with allopurinol. 
Zdravilo Zurampic so proučevali v dveh glavnih študijah, ki sta vključevali več kot 1 200 odraslih s protinom, ki so se predhodno zdravili z alopurinolom.
Why is Zurampic approved? 
Zakaj je bilo zdravilo Zurampic odobreno?
Adding Zurampic 200 mg once daily was effective in 55% (222 of 405) patients. 
Dodajanje zdravila Zurampic 200 mg enkrat na dan je bilo učinkovito pri 55 % (222 od 405) bolnikov.
Looking just at patients whose blood uric acid level did not fall sufficiently on treatment with febuxostat alone, the level dropped to less than 50 mg/litre in 44% (26 of 59) patients taking Zurampic compared to 24% (12 of 51) patients taking placebo. 
Med bolniki, pri katerih se koncentracija sečne kisline v krvi ob zdravljenju samo s febuksostatom ni dovolj znižala, se je njena koncentracija znižala na manj kot 50 mg/liter pri 44 % (26 od 59) bolnikov, ki so prejemali zdravilo Zurampic, v primerjavi s 24 % (12 od 51) bolnikov, ki so prejemali placebo.
A third main study involved 324 adults who had at least one measurable tophus (large deposit of uric acid in or around a joint or under the skin) and with high blood levels of uric acid (over 80 mg/litre without gout medicines or above 60 mg/litre despite treatment with allopurinol or febuxostat). 
Tretja glavna študija je vključevala 324 odraslih, ki so imeli vsaj en merljiv tof (velika zaloga sečne kisline v sklepu ali okoli njega ali pod kožo) in visoko koncentracijo sečne kisline (nad 80 mg/liter brez zdravila za protin ali nad 60 mg/liter kljub zdravljenju z alopurinolom ali febuksostatom).
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zurampic, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The company that markets Zurampic will carry out a study on the risk of heart, circulation or kidney disorders in patients treated with Zurampic, particularly in those who have previously suffered from such disorders. 
Družba, ki trži zdravilo Zurampic, bo izvedla študijo o tveganjih za nastanek bolezni srca, ožilja ali ledvic pri bolnikih, ki se zdravijo z zdravilom Zurampic, zlasti pri tistih, ki so že imeli te bolezni.
Overall, Zurampic 200 mg once daily was effective in 57% (60 of 106) patients. 
Skupno je bilo zdravilo Zurampic 200 mg enkrat na dan učinkovito pri 57 % (60 od 106) bolnikov.
The most common side effects with Zurampic (which may affect up to 1 in 10 people) are flu, headache, heartburn and (gastro-oesophageal reflux disease) stomach acid coming back to the mouth, and blood tests showing increased blood creatinine levels (a marker of kidney function). 
Najpogostejši neželeni učinki zdravila Zurampic (ki lahko prizadenejo največ 1 osebo od 10) so gripa, glavobol, zgaga in (gastroezofagealna refluksna bolezen) vračanje želodčne kisline nazaj v usta ter izvidi krvnih preiskav, ki kažejo na zvišano koncentracijo kreatinina v krvi (označevalec delovanja ledvic).
For more information about treatment with Zurampic, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Zurampic preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The most serious adverse reactions were kidney failure, reduced kidney function, and kidney stones, which affected less than 1 patient in 100. 
Najresnejši neželeni učinki so bili ledvična odpoved, okvarjeno delovanje ledvic in ledvični kamni, prizadeli pa so manj kot 1 osebo od 100.
Patients must not take Zurampic if they suffer from tumour lysis syndrome (a complication due to the rapid breakdown of cancer cells during cancer treatment) or a rare hereditary disease called LeschNyhan syndrome, both of which raise uric acid levels in the blood. 
Bolniki ne smejo jemati zdravila Zurampic, če imajo sindrom lize tumorja (zaplet zaradi hitre razgradnje rakavih celic med zdravljenjem zaradi raka) ali redko dedno bolezen, imenovano Lesch-Nyhanov sindrom; oba sindroma namreč dvigneta koncentracijo sečne kisline v krvi.
It does this by blocking a protein called ‘uric acid transporter-1' (URAT1) in the kidneys. 
To doseže tako, da blokira beljakovino, imenovano prenašalec sečne kisline 1 (URAT1), v ledvicah.
These studies compared the effect of adding Zurampic or placebo (a dummy treatment) to patients' allopurinol treatment. 
V teh študijah so primerjali učinek dodajanja zdravila Zurampic ali placeba (zdravila brez zdravilne učinkovine) zdravljenju z alopurinolom.
This compared with 47% (51 of 109) patients given placebo. 
Ta delež je pri bolnikih, ki so prejemali placebo, znašal 47 % (51 od 109).